Clinical trial
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00087789 · Sangamo Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00087789 |
|---|---|
| Title | CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease |
| Official title | A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Sangamo Therapeutics, Industry |
| Collaborators | Ceregene Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Genetic |
| Interventions | CERE-110: Adeno-Associated Virus Delivery of NGF |
| Enrollment | 10 |
| Start date | Jun 1, 2004 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Jul 16, 2004 |
| Last update posted | Nov 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: